ライフサイエンスコーパス: antibody-dependent cellular cytotoxicity

1 get IL-5R and attenuate eosinophilia through antibody-dependent cellular cytotoxicity.

2 th IgG Fc-mediated complement activation and antibody-dependent cellular cytotoxicity.

3 ors via complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity.

4 ody for easy-to-neutralize SIV isolates, and antibody-dependent cellular cytotoxicity.

5 r natural killer cells, nor does it diminish antibody-dependent cellular cytotoxicity.

6 ivation of PP2A also decreases human NK-cell antibody-dependent cellular cytotoxicity.

7 diates complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.

8 esponse, presumably because of their role in antibody-dependent cellular cytotoxicity.

9 zing antibody titers and better induction of antibody-dependent cellular cytotoxicity.

10 suggesting that it is mediated by a form of antibody-dependent cellular cytotoxicity.

11 -mediated phagocytosis, oxidative burst, and antibody-dependent cellular cytotoxicity.

12 ents C1q, C3, C5, and properdin and blocking antibody-dependent cellular cytotoxicity.

13 for immune responses such as phagocytosis or antibody-dependent cellular cytotoxicity.

14 ces from diverse HIV-1 isolates and mediated antibody-dependent cellular cytotoxicity.

15 ces from diverse HIV-1 isolates and mediated antibody-dependent cellular cytotoxicity.

16 -induced (CD4i) antibodies capable of potent antibody-dependent cellular cytotoxicity.

17 elevated natural cytotoxicity, and increased antibody-dependent cellular cytotoxicity.

18 enhancing NK cell-mediated cytotoxicity and antibody-dependent cellular cytotoxicity.

19 ediated by donor-specific antibodies through antibody-dependent cellular cytotoxicity.

20 us virion capture, virus neutralization, and antibody-dependent cellular cytotoxicity.

21 Complement- and antibody-dependent cellular cytotoxicity-activating func

22 g to FcgammaRIIIA and thereby decreasing the antibody-dependent cellular cytotoxicity activities.

23 te fucose-deficient antibodies with enhanced antibody-dependent cellular cytotoxicity activities.

24 No alteration in gamma-receptor binding and antibody-dependent cellular cytotoxicity activity was ob

25 dy incapable of Fcgamma receptor binding and antibody-dependent cellular cytotoxicity activity, aboli

26 ed with higher serum binding titer, stronger antibody-dependent cellular cytotoxicity activity, and p

27 by generation of reactive oxygen species or antibody-dependent cellular cytotoxicity activity, but l

28 immunoglobulin that may cooperatively elicit antibody-dependent cellular cytotoxicity activity.

29 versely affect the ability of mAbs to induce antibody dependent cellular cytotoxicity (ADCC).

30 antibodies (Abs), those capable of mediating antibody-dependent cellular cytotoxicity (ADCC) activity

31 oclonal antibodies and subsequently modulate antibody-dependent cellular cytotoxicity (ADCC) activity

32 (Abs) to the V1V2 region of gp120 with high antibody-dependent cellular cytotoxicity (ADCC) activity

33 and that this protection may correlate with antibody-dependent cellular cytotoxicity (ADCC) activity

34 lobulin G1 antibody variant with compromised antibody-dependent cellular cytotoxicity (ADCC) activity

35 ust cross-clade binding and neutralizing and antibody-dependent cellular cytotoxicity (ADCC) activity

36 ngly, the presence of antibodies with potent antibody-dependent cellular cytotoxicity (ADCC) activity

37 Both 42F and 43F directed substantial antibody-dependent cellular cytotoxicity (ADCC) against

38 ility to opsonize viral particles, to direct antibody-dependent cellular cytotoxicity (ADCC) against

39 b) directs natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against

40 The ALVAC/AIDSVax vaccine induced antibody-dependent cellular cytotoxicity (ADCC) against

41 The antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) against

42 Antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) against

43 cantly greater antibody activities mediating antibody-dependent cellular cytotoxicity (ADCC) and anti

44 iminating latent HIV infection, specifically antibody-dependent cellular cytotoxicity (ADCC) and anti

45 Antibody-dependent cellular cytotoxicity (ADCC) and comp

46 IgG1 b12 mediated strong antibody-dependent cellular cytotoxicity (ADCC) and comp

47 2 immune functions, cytomegalovirus-specific antibody-dependent cellular cytotoxicity (ADCC) and natu

48 These Treg suppressed cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) and thei

49 munodeficiency virus type 1 (HIV-1)-specific antibody-dependent cellular cytotoxicity (ADCC) antibody

50 To investigate antibody-dependent cellular cytotoxicity (ADCC) as a con

51 In vitro antibody-dependent cellular cytotoxicity (ADCC) assays i

52 y-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) assays w

53 However, in 2 HSV-2 antibody-dependent cellular cytotoxicity (ADCC) assays,

54 phagocytosis, NK cell activation assays, and antibody-dependent cellular cytotoxicity (ADCC) assays.

55 ed cells at all doses and a 52% reduction in antibody-dependent cellular cytotoxicity (ADCC) at doses

56 riggered lysis of multiple myeloma cells via antibody-dependent cellular cytotoxicity (ADCC) but did

57 Natural killer (NK) immune cells mediate antibody-dependent cellular cytotoxicity (ADCC) by aggre

58 ycan fucosylation have been shown to improve antibody-dependent cellular cytotoxicity (ADCC) by allow

59 eptor expressed on NK cells that facilitates antibody-dependent cellular cytotoxicity (ADCC) by bindi

60 ee medium, but had not been shown to inhibit antibody-dependent cellular cytotoxicity (ADCC) by CD16+

61 Antibody-dependent cellular cytotoxicity (ADCC) by immun

62 Growing evidence indicates antibody-dependent cellular cytotoxicity (ADCC) contribu

63 g antibodies with effector functions such as antibody-dependent cellular cytotoxicity (ADCC) contribu

64 The characteristics of antibody-dependent cellular cytotoxicity (ADCC) directed

65 ible (CDi) neutralizing epitopes targeted by antibody-dependent cellular cytotoxicity (ADCC) effector

66 ll-sorting (FACS) analysis, and had enhanced antibody-dependent cellular cytotoxicity (ADCC) effector

67 oss-reactive antibodies capable of mediating antibody-dependent cellular cytotoxicity (ADCC) effector

68 onses at an early time point correlated with antibody-dependent cellular cytotoxicity (ADCC) function

69 virus type 1 (HIV-1) Env and able to mediate antibody-dependent cellular cytotoxicity (ADCC) have bee

70 ng evidence supports a role for HIV-specific antibody-dependent cellular cytotoxicity (ADCC) in contr

71 Although anti-CD52 functions primarily by antibody-dependent cellular cytotoxicity (ADCC) in vivo,

72 -HIV-1 Env IgA antibodies and high levels of antibody-dependent cellular cytotoxicity (ADCC) inversel

73 Antibody-dependent cellular cytotoxicity (ADCC) is media

74 16-mediated NK cell IFN-gamma production and antibody-dependent cellular cytotoxicity (ADCC) is uncle

75 Antibody-dependent cellular cytotoxicity (ADCC) may be a

76 Therefore, antibody-dependent cellular cytotoxicity (ADCC) may play

77 Nonneutralizing antibodies (Abs) involved in antibody-dependent cellular cytotoxicity (ADCC) may prov

78 and neutrophils for killing of L3 through an antibody-dependent cellular cytotoxicity (ADCC) mechanis

79 able to induce complement-mediated lysis and antibody-dependent cellular cytotoxicity (ADCC) of trans

80 uce CD16 modulation, CD54 up-regulation, and antibody-dependent cellular cytotoxicity (ADCC) on NK ce

81 Elimination of HIV-1-infected cells by antibody-dependent cellular cytotoxicity (ADCC) requires

82 levels of HIV-1-neutralizing antibodies and antibody-dependent cellular cytotoxicity (ADCC) response

83 itopes) as targets of potentially protective antibody-dependent cellular cytotoxicity (ADCC) response

84 ding IgG and IgA as well as neutralizing and antibody-dependent cellular cytotoxicity (ADCC) response

85 XmAb5592 increased antibody-dependent cellular cytotoxicity (ADCC) several

86 complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through

87 ith prechallenge serum antienvelope avidity, antibody-dependent cellular cytotoxicity (ADCC) titers,

88 There is growing interest in utilizing antibody-dependent cellular cytotoxicity (ADCC) to elimi

89 e HIV-1 reservoir.IMPORTANCE Mobilization of antibody-dependent cellular cytotoxicity (ADCC) to elimi

90 protein expressed by infected cells mobilize antibody-dependent cellular cytotoxicity (ADCC) to elimi

91 In the secondary analysis, antibody-dependent cellular cytotoxicity (ADCC) was anot

92 tes biological effector functions, including antibody-dependent cellular cytotoxicity (ADCC) which is

93 ating the factors that modulate HIV-specific antibody-dependent cellular cytotoxicity (ADCC) will hel

94 t PBMC also kill antibody-opsonized cells by antibody-dependent cellular cytotoxicity (ADCC), a react

95 Complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), and apo

96 e breadth of HIV-1 gp120 and V1V2 responses, antibody-dependent cellular cytotoxicity (ADCC), and low

97 The MAbs mediated antibody-dependent cellular cytotoxicity (ADCC), and mic

98 Very high IgG binding titers, substantial antibody-dependent cellular cytotoxicity (ADCC), and mod

99 b triggers natural killer (NK)-cell-mediated antibody-dependent cellular cytotoxicity (ADCC), but lit

100 rituximab-mediated antitumor effects include antibody-dependent cellular cytotoxicity (ADCC), complem

101 s may mediate protective effects by means of antibody-dependent cellular cytotoxicity (ADCC), in whic

102 functions, including tier 1 neutralization, antibody-dependent cellular cytotoxicity (ADCC), infecte

103 ide, an immunomodulatory agent that enhances antibody-dependent cellular cytotoxicity (ADCC), is curr

104 hermore, HCD122 is also a potent mediator of antibody-dependent cellular cytotoxicity (ADCC), lysing

105 we demonstrate that XmAb5574 mediates potent antibody-dependent cellular cytotoxicity (ADCC), modest

106 ed up to 3 mg of mAb that possesses enhanced antibody-dependent cellular cytotoxicity (ADCC), nonanti

107 cts on virus infectivity, antibodies mediate antibody-dependent cellular cytotoxicity (ADCC), the kil

108 ese epitopes and sensitize infected cells to antibody-dependent cellular cytotoxicity (ADCC), we trea

109 e, core fucosylation significantly decreases antibody-dependent cellular cytotoxicity (ADCC), whereas

110 One such mechanism is antibody-dependent cellular cytotoxicity (ADCC), whereby

111 Polymorphonuclear leukocytes (PMNs) mediate antibody-dependent cellular cytotoxicity (ADCC), which i

112 Fc N-glycans leads to drastic enhancement of antibody-dependent cellular cytotoxicity (ADCC), while t

113 Cross-reactive influenza virus-specific antibody-dependent cellular cytotoxicity (ADCC)-activati

114 ed that human natural killer (NK) cells, via antibody-dependent cellular cytotoxicity (ADCC)-like mec

115 tion with either lineage induces HA-specific antibody-dependent cellular cytotoxicity (ADCC)-mediatin

116 tumor cells by several mechanisms, including antibody-dependent cellular cytotoxicity (ADCC).

117 es, possibly owing to its ability to mediate antibody-dependent cellular cytotoxicity (ADCC).

118 through Fc receptors by antibodies mediating antibody-dependent cellular cytotoxicity (ADCC).

119 ed rituximab binding and rituximab-mediated, antibody-dependent cellular cytotoxicity (ADCC).

120 critical role in Fc receptor (FcR)-mediated antibody-dependent cellular cytotoxicity (ADCC).

121 ch antibodies can exert cytotoxic effects is antibody-dependent cellular cytotoxicity (ADCC).

122 One potential mechanism of action involves antibody-dependent cellular cytotoxicity (ADCC).

123 , complement-dependent cell lysis (CDC), and antibody-dependent cellular cytotoxicity (ADCC).

124 ncreases susceptibility of infected cells to antibody-dependent cellular cytotoxicity (ADCC).

125 (NK)-cell degranulation and NK-cell-mediated antibody-dependent cellular cytotoxicity (ADCC).

126 d rafts and is glycoengineered for augmented antibody-dependent cellular cytotoxicity (ADCC).

127 dividuals contain antibodies able to mediate antibody-dependent cellular cytotoxicity (ADCC).

128 inate cells reactivated from latency through antibody-dependent cellular cytotoxicity (ADCC).

129 lso kills MET-overexpressing cancer cells by antibody-dependent cellular cytotoxicity (ADCC).

130 ve demonstrated that CD4i antibodies mediate antibody-dependent cellular cytotoxicity (ADCC).

131 d NK cell degranulation and NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC).

132 of tumour-infiltrating regulatory T cells by antibody-dependent cellular cytotoxicity (ADCC).

133 ugh Fc receptor-dependent processes, such as antibody-dependent cellular cytotoxicity (ADCC).

134 xtensively studied for its role in mediating antibody-dependent cellular cytotoxicity (ADCC).

135 t complement-dependent cytotoxicity (CDC) or antibody-dependent cellular-cytotoxicity (ADCC), so as t

136 infected cells by natural killer (NK) cells (antibody-dependent cellular cytotoxicity [ADCC]) or comp

137 Antibody-dependent cellular cytotoxicity against ARH-77

138 tosis in the presence of a cross-linker, and antibody-dependent cellular cytotoxicity against B-cell

139 While antibody-dependent cellular cytotoxicity against gp120 d

140 nt, enhances NK-cell direct cytotoxicity and antibody-dependent cellular cytotoxicity against hematop

141 cking core N-glycan residues mediated higher antibody-dependent cellular cytotoxicity against human t

142 An afucosylated Fc form (Pr20M) directed antibody-dependent cellular cytotoxicity against PRAME+H

143 atural killer cells with concurrent enhanced antibody-dependent cellular cytotoxicity against rituxim

144 fic CD16(pos) gammadelta T cells can perform antibody-dependent cellular cytotoxicity against stromal

145 The CEA-specific antibodies mediated antibody-dependent cellular cytotoxicity against tumor c

146 ed in N. benthamiana are capable of inducing antibody-dependent cellular cytotoxicity, an activity no

147 e that immunostimulatory CpG ODN can enhance antibody dependent cellular cytotoxicity and warrant fur

148 ti-IL1RAP antibody capable of both achieving antibody-dependent cellular cytotoxicity and blocking of

149 pecific monoclonal antibodies display robust antibody-dependent cellular cytotoxicity and CD4-depende

150 y programmed immune responses were driven by antibody-dependent cellular cytotoxicity and complement-

151 nal epitopes and mediated both AQP4-directed antibody-dependent cellular cytotoxicity and complement-

152 osed for this therapeutic antibody including antibody-dependent cellular cytotoxicity and complement-

153 ) can induce lysis of neuroblastoma cells by antibody-dependent cellular cytotoxicity and complement-

154 The antibody-dependent cellular cytotoxicity and complement-

155 tes killing of infected cells by Fc-mediated antibody-dependent cellular cytotoxicity and complement-

156 f a CD20-targeting antibody had no impact on antibody-dependent cellular cytotoxicity and did not cha

157 emistry, and a target for cetuximab-mediated antibody-dependent cellular cytotoxicity and in vivo eli

158 different cell surface antigens, but not to antibody-dependent cellular cytotoxicity and lymphokine-

159 ne phosphorylation during the development of antibody-dependent cellular cytotoxicity and natural kil

160 redicted susceptibility to cetuximab-induced antibody-dependent cellular cytotoxicity and occurred in

161 tes immunological effector functions such as antibody-dependent cellular cytotoxicity and phagocytosi

162 -negative tumor cells were resistant to both antibody-dependent cellular cytotoxicity and signaling-i

163 lear leukocytes and macrophages that mediate antibody-dependent cellular cytotoxicity and/or trigger

164 ion by activating innate immunity, enhancing antibody dependent cellular cytotoxicity, and serving as

165 both macrophage-dependent FcgammaR-mediated antibody-dependent cellular cytotoxicity, and by direct

166 ability of lumiliximab to mediate apoptosis, antibody-dependent cellular cytotoxicity, and complement

167 ng of infected targets through direct lysis, antibody-dependent cellular cytotoxicity, and production

168 ate effector pathways, such as phagocytosis, antibody-dependent cellular cytotoxicity, and the recrui

169 arcinoma cells were shown to be sensitive to antibody-dependent cellular cytotoxicity, and their in v

170 including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, antibody-depen

171 le mechanisms including apoptosis induction, antibody-dependent cellular cytotoxicity, antibody-depen

172 Moreover, in antibody-dependent cellular cytotoxicity assays against

173 Antibody-dependent cellular cytotoxicity assays using pu

174 odification in the Fc domain that eliminates antibody-dependent cellular cytotoxicity at clinically r

175 gest that enhancement of Fc gamma R-mediated antibody-dependent cellular cytotoxicity by inflammatory

176 ivation of the classical complement pathway, antibody-dependent cellular cytotoxicity by innate immun

177 proved complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity compared with r

178 The 20-2b shows enhanced antibody-dependent cellular cytotoxicity compared with v

179 uce Fc-mediated effector functions including antibody-dependent cellular cytotoxicity, complement-dep

180 pe glycans and reported to display increased antibody-dependent cellular cytotoxicity, demonstrates t

181 s, of which the major mechanism of action is antibody-dependent cellular cytotoxicity (eg, trastuzuma

182 he asymmetrically engineered Fc variants for antibody-dependent cellular cytotoxicity enhancement cou

183 an anti-CD38 monoclonal antibody in reverse antibody-dependent cellular cytotoxicity experiments, it

184 The in vivo half-life, antibody-dependent cellular cytotoxicity function, and b

185 Specific killing of C15 cells in in vitro antibody-dependent cellular cytotoxicity has been observ

186 ation and degradation and mediates effective antibody-dependent cellular cytotoxicity in a variety of

187 ing of CD16 (Fc gamma RIIIA), which mediates antibody-dependent cellular cytotoxicity in LAKs, also l

188 These include activation of antibody-dependent cellular cytotoxicity, inhibition of

189 Natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity involving Fcgam

190 3-specific and fusion-inhibition antibodies, antibody-dependent cellular cytotoxicity, lymphoprolifer

191 This can likely be ascribed to the antibody-dependent cellular cytotoxicity machinery becau

192 FL, mechanisms of tumor clearance other than antibody-dependent cellular cytotoxicity may be more imp

193 We consider two alternatives: the first, antibody-dependent cellular cytotoxicity mediated by FcR

194 2M activates natural killer cells to enhance antibody-dependent cellular cytotoxicity, mediates compl

195 ) arm that was derived from broadly binding, antibody-dependent cellular cytotoxicity-mediating antib

196 highest titers of binding, neutralizing, and antibody-dependent cellular cytotoxicity-mediating antib

197 ecific MAbs that showed Galcer blocking, the antibody-dependent cellular cytotoxicity-mediating CH38

198 Our study highlights the potential role that antibody-dependent cellular cytotoxicity might play in a

199 gocytosis of antibody-coated tachyzoites nor antibody-dependent cellular cytotoxicity nor antibody-an

200 diates complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity of CD20-positiv

201 dy inhibits cell growth and induces in vitro antibody-dependent cellular cytotoxicity of human neurob

202 ne neutralization of RANKL with induction of antibody-dependent cellular cytotoxicity of natural kill

203 Unlike rituximab, hLL1 did not induce antibody-dependent cellular cytotoxicity or complement-m

204 mulation, by the use of antibodies to induce antibody-dependent cellular cytotoxicity or to block iKI

205 d functional activity (virus neutralization, antibody-dependent cellular cytotoxicity, phagocytosis,

206 nses can be induced through the induction of antibody-dependent cellular cytotoxicity, promotion of a

207 NSCC sensitivity in a manner associated with antibody-dependent cellular cytotoxicity rather than EGF

208 which eosinophils mediate tissue injury and antibody-dependent cellular cytotoxicity reactions.

209 levels of IgA antibodies, and high levels of antibody-dependent cellular cytotoxicity responses and H

210 In each study, protection correlated with antibody-dependent cellular cytotoxicity specific for CD

211 1 Fc protein variant that exhibited enhanced antibody-dependent cellular cytotoxicity, the lack of fu

212 f natural killer cells, the key mediators of antibody-dependent cellular cytotoxicity, to human AMR i

213 ariety of rodent tumor models by stimulating antibody-dependent cellular cytotoxicity toward tumor ve

214 sis of Fc gamma R+ target cells in a reverse antibody-dependent cellular cytotoxicity-type assay and

215 a generalized defect in cytotoxicity because antibody-dependent cellular cytotoxicity was intact.

216 Antibody-dependent cellular cytotoxicity was not require

217 IFN-gamma treatment of monocytes enhanced antibody-dependent cellular cytotoxicity, whereas IFN-ga

218 biting complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, which suggests

219 In addition, the antibodies did not manifest antibody-dependent cellular cytotoxicity with NOD/SCID s